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Unifying Hypothesis*
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The epidemiologic association between cigarette smoking
and atherosclerosis is firmly established. The degree of pre-
disposition to coronary artery disease is clearly related to
the number of cigarettes smoked. Numerous studies (I) have
demonstrated that chronic smokers are at increased risk of
myocardial infarction and sudden death. Furthermore, those
who discontinue smoking are at less risk for cardiac events
than those who continue to smoke.
The precise mechanism by which smoking contributes to
the development and clinical manifestations of coronary
disease is unknown. In this issue of the Journal, Nicod et
al. (2) report their observations of the acute effects of smok-
ing on coronary hemodynamics and myocardial metabolism.
Their findings and those of other recent investigations sug-
gest that cigarette smoking increases coronary tone in pa-
tients with coronary disease, either at the site of a significant
coronary stenosis or in the distal arteriolar bed. Smoking
also has detectable vasoconstrictor properties in the normal
coronary vasculature. It is tempting to speculate that a link
exists between these pathophysiologic effects and the known
clinical sequelae of cigarette smoking.
An attractive hypothesis to consider is that chronic smok-
ing predisposes to accelerated coronary atherosclerosis, at
least in part, as a consequence of a cumulation of its acute
effects on coronary vasomotor tone. Frequent episodes of
acute vascular stress may lead to recurrent coronary vaso-
constriction and intimal damage, a potentially important
factor in the development of atherosclerosis. Since smoking
also promotes platelet aggregability, the interaction between
platelets and the vascular endothelium is substantially al-
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teredo Thus, in the presence of established coronary disease,
smoking results both in increased thrombogenicity and in-
creased coronary tone, which could lead to myocardial in-
farction and sudden death. Importantly, the incidence of
these events is decreased with the cessation of smoking,
suggesting that this vasoconstricted and thrombogenic mil-
lieu is potentially reversible.
Effects of Chronic Smoking
Coronary reactivity. Chronic cigarette smoking has a
demonstrable vasoconstrictor effect on the coronary vas-
culature. Chronic smokers have reduced coronary vascular
reserve despite angiographically normal coronary arteries
(3). The degree of reduction in the reactive hyperemic re-
sponse is related to the amount of prior smoking. This ob-
servation implies a diminished capacity of the arteriolar bed
to vasodilate and compensate for the potential induction of
myocardial ischemia, both in patients with coronary disease
and in normal persons. Its possible relation to the occurrence
of ischemia in patients with normal coronary angiograms
has been noted (4). It may also be partially responsible for
the decreased exercise tolerance seen in chronic smokers
(5).
The mechanism causing decreased coronary reactivity
may be related to nicotine-induced reductions in vascular
endothelial prostacyclin (Prostaglandin12 lPGlz]) levels (6-8).
Wennmalm and Alster (6,7) found that both cigarette smok-
ing and indomethacin inhibit the reactive hyperemic re-
sponse in the limb, but that smoking has no additional effect
after indomethacin administration. This suggests that both
interventions work by the same mechanism, presumably
prostaglandin inhibition. Nicotine has peen shown to de-
crease PGlz synthesis in vascular endothelium, but to have
no effect on thromboxane A2 production (7). Interestingly,
chronic smokers have recently been shown to have reduced
PGI2 levels in the systemic circulation (8,9) and in the
coronary sinus (2,8) as compared with nonsmokers.
Coronary atherosclerosis. Chronic smoking alters
endothelial structure, denudes the surface of the vessel and
promotes platelet adhesion to subendothelial layers (10).
These structural changes are believed to be important factors
in the development of atherosclerosis (11). Kannel (12) has
suggested that the carbon monoxide in cigarette smoke
produces endothelial hypoxia, allowing intimal lipid infil-
tration; in addition, enhanced platelet adhesion to the sub-
endothelial layers may stimulate intimal smooth muscle
proliferation, perhaps through prostaglandin-mediated
mechanisms.
Furthermore, this alteration in vascular integrity might
explain the decreased PGI2 levels in chronic smokers (13).
Alternatively, the endothelial changes could be the result
0735-1097184/$3.00





of persistently increased coronary tone mediated by de-
creased PGI2 synthesis. Increased coronary resistance could
result in increased turbulence and shear forces, causing
endothelial damage as has been shown in hydraulic models.
In addition, the decreased PGh levels take on further sig-
nificance in view of the theory that a disequilibrium between
prostacyclin and thromboxane may be an important factor
in the pathogenesis of atherosclerosis. Thus, increased
vasomotor tone may represent the connection between chronic
smoking and atherosclerotic cardiovascular disease.
Acute Hemodynamic Effects of Smoking
An individual who smokes one pack of cigarettes per
day acutely stresses his or her cardiovascular system 20
times in 24 hours. It is possible that these chronic coronary
vascular changes are the result of frequent and repeated
episodes of acute systemic and coronary arterial hemody-
namic stress sustained over the course of years.
Systemic hemodynamics. Cigarette smoking causes in-
creases in heart rate, systolic blood pressure and cardiac
output in normal individuals. The neural and hormonal
mechanisms that mediate this response have recently been
reviewed (14). Direct sympathetic ganglionic stimulation
and activation of several neural reflexes produce peripheral
vasoconstriction. Systemic blood pressure increases as a
consequence of the increased peripheral resistance. Heart
rate increases because of direct chronotropic effects and
adrenal catecholamine secretion. Although myocardial con-
tractility increases because of the catecholamine effect,
changes in stroke volume vary considerably. Cardiac output
increases chiefly through the increase in heart rate.
Coronary hemodynamics. These systemic effects aug-
ment the workload of the heart. The observed increases in
heart rate, afterload and contractility serve to increase myo-
cardial oxygen demand. Elevated carboxyhemoglobin levels
reduce the capacity for oxygen exchange in the capillary
beds, which has a deleterious effect on myocardial cellular
aerobic metabolism. Therefore, the net result of cigarette
smoking is to increase myocardial oxygen demand and limit
myocardial oxygen supply. Smoking increases arterial-coro-
nary sinus oxygen differences in normal individuals, pro-
viding evidence of the increase in myocardial oxygen con-
sumption (15). In response, coronary blood flow increases
to prevent an imbalance between oxygen supply and demand
(15). Atrial pacing data in patients with nonobstructive coro-
nary disease before and after smoking demonstrate that the
coronary flow response is blunted after smoking (16). Thus,
although the normal coronary response to smoking is a de-
crease in coronary resistance and an increase in flow, there
is evidence that acute smoking diminishes the coronary
reserve.
In patients with coronary artery disease, however, this
response is markedly altered despite a similar and often
higher myocardial oxygen consumption (15). The coronary
flow response is heterogeneous and depends on the site and
severity of coronary lesions. Klein et al. (15) and Nicod et
al. (2) observed that in many patients with proximal coro-
nary obstructions, coronary resistance increases and coro-
nary blood flow decreases with smoking. Vasoconstrictor
responses are less prominent in patients with distal lesions.
A preliminary study by Booth et al. (17) in which both great
cardiac vein and coronary sinus flows were measured during
smoking, as well as our own data, are consistent with the
hypothesis that resistance increases in regions subtended by
a significant coronary stenosis and decreases in normal re-
gions. These observations suggest that there is an active
response to cigarette smoking that results in diminished
oxygen supply to myocardium distal to a coronary stenosis.
Measurements of coronary blood flow performed during
atrial pacing before and after smoking (16,18) also suggest
that cigarette smoke has vasoconstrictor effects in patients
with obstructive coronary disease. Coronary flow does not
increase as much for the same rate-pressure product (16) as
compared with the flows achieved before smoking. The
threshold to angina also decreases (18), further implying
that acute smoking decreases the coronary reserve. The re-
sults of Nicod et al. (2) in this issue confirm these findings.
There are several potential explanations for these ob-
servations. Smoking may increase tone at the site of the
coronary stenosis, causing decreased blood flow to the distal
myocardial bed (15). Although the concept of a coronary
atherosclerotic lesion having dynamic features is accepted,
the mechanism involved in changes in luminal dimension
is not known (19). Stimulation of coronary alpha-adrenergic
receptors by nicotine or the catecholamines released with
smoking could result in arterial smooth muscle contraction
around the stenosis, decreasing the lumen diameter (12).
Conceivably, inhibition of a local metabolite with potent
vasodilator properties, such as PGh, would be another pos-
sible stimulus for such smooth muscle contraction. Nadler
et al. (20,21) recently observed acute inhibition of urinary
PGh excretion with smoking. Mehta and Mehta (9) found
a much smaller increase in plasma PGh than in thromboxane
A2; however, Nicod et al. (2) and Martin et al. (8) reported
no significant changes in aortic or coronary sinus PG121eveis
with smoking. The differences in the findings of these stud-
ies might be explained on the basis of methodologic prob-
lems. The plasma assay for 6 keto-immunoactivity may
cross-react with other prostaglandins, and might not accu-
rately reflect PGI2 levels. Also, because prostaglandins are
active only at the site of their release, measurements of
metabolites in a distant, central area may not be represen-
tative of acute changes in regional levels. Thus, the pos-
sibility remains that smoking increases coronary tone at the
site of a stenosis by causing small decreases in local PGI2
levels without compensatory changes in thromboxane A2
levels, which has counterbalancing vascular effects (22,23).
As suggested by Nicod et al. (2), the decreased PGh
levels and increased circulating catecholamines could also
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act by increasing platelet activation, resulting in intermittent
platelet aggregation and "plugging" in the stenosis lumen.
Experimental data in dog models have shown that obstruc-
tion from platelet aggregation in a mechanically constricted
lumen can cause blood flow reductions (24), an effect ex-
acerbated by nicotine and cigarette smoke (25). However,
no changes in platelet aggregability or platelet factor IV
levels in the coronary sinus have been reported after smoking
(26, and Martin JL, personal communication). Importantly,
either of these PGlz-mediated effects could also occur in
the microvasculature distal to the coronary stenosis, as could
catecholamine-mediated adrenergic stimulation. Either local
vasoconstrictor effects or intermittent platelet plugging in
the small resistive arterioles would explain the observed flow
responses. It should be noted that we have not observed
angiographic evidence of changes in coronary stenosis cal-
iber with smoking. However, small changes in lumen di-
ameter beyond the limitations of angiographic visual inter-
pretation may have important effects on the flow through a
critical lesion (19).
Conclusion
There is increasing evidence to support the hypothesis
that smoking-induced changes in coronary vasomotor tone,
platelet activation and endothelial integrity are a major com-
ponent of the development of atherosclerosis and the oc-
currence of subsequent cardiac events. The acute coronary
hemodynamic response to cigarette smoking appears to be
a reflection of induced alterations in the hormonal and local
metabolic constitution of the coronary vasculature. Chronic
smoking results in a vasoconstricted coronary bed, probably
through the sum of its acute effects on both the prostacyclin:
thromboxane ratio and catecholamine secretion. Smoking
may accelerate the progression of atherosclerosis by injuring
the vascular intima, possibly as the result of persistently
increased coronary artery tone and frequent episodes of
hemodynamic stress, and by raising the serum cholesterol
(27). Finally, in the presence of a severe coronary lesion,
vasoconstriction or enhanced platelet aggregation, or both,
at the site of the lesion may explain the increased likelihood
of acute cardiac events in chronic smokers and the improved
prognosis in those who quit. Further investigation in each
of these areas will be necessary before the veracity of this
hypothesis can be determined.
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